AnaptysBio, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $25.6 million, a decrease from $27.8 million in the same period last year. The company recorded a net loss of $52.9 million, compared to a loss of $39.3 million in the first quarter of 2025. The increase in net loss was attributed to higher general and administrative expenses, which rose to $26.2 million from $14.1 million, largely due to legal costs associated with ongoing litigation and the company's recent separation into two independent entities.
Total operating expenses for the quarter were $60.2 million, up from $55.3 million in the prior year. Research and development expenses decreased to $34.0 million from $41.2 million, primarily due to reduced clinical expenses. The company’s cash and cash equivalents increased to $248.5 million as of March 31, 2026, compared to $238.2 million at the end of 2025, reflecting a net increase of $10.3 million during the quarter.
In terms of strategic developments, AnaptysBio completed the separation of its business into two independent publicly traded companies on April 20, 2026. This separation allows AnaptysBio to focus on managing its royalty agreements, particularly with GSK for the drug Jemperli, while the new entity, First Tracks Biotherapeutics, will concentrate on the development of immunology therapeutics. The separation is expected to streamline operations and enhance shareholder value, although it may also involve ongoing costs and management challenges.
Operationally, the company reported a decrease in collaboration revenue from its GSK partnership, which is primarily driven by royalties from Jemperli. The company recognized $25.5 million in royalty revenue during the first quarter of 2026, compared to $18.1 million in the same period last year. This revenue is non-cash due to the monetization agreements in place. The company anticipates fluctuations in future revenues based on the performance of its collaborators and market conditions.
Looking ahead, AnaptysBio expressed confidence that its existing cash reserves will support its operations for at least the next 12 months. However, the company acknowledged the potential need for additional financing to support its strategic initiatives. The management remains focused on navigating the complexities of the recent separation and ensuring the continued success of its collaborations, particularly with GSK, as it seeks to maximize the value of its royalty streams.
About ANAPTYSBIO, INC
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead product, rosnilimab, targets PD-1+ T cells and is in Phase 2b trials for rheumatoid arthritis and ulcerative colitis. With a focus on underserved patient populations, AnaptysBio aims to leverage its antibody pipeline and collaborations, including with GlaxoSmithKline, to address significant market opportunities in immunology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.